The estimated Net Worth of Domenic Serafino is at least $1.31 Milhão dollars as of 30 August 2022. Mr Serafino owns over 75,000 units of Venus Concept stock worth over $544,628 and over the last 5 years he sold VERO stock worth over $0. In addition, he makes $763,479 as CEO & Director at Venus Concept.
Mr has made over 7 trades of the Venus Concept stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 75,000 units of VERO stock worth $24,750 on 30 August 2022.
The largest trade he's ever made was exercising 326,589 units of Venus Concept stock on 20 November 2020 worth over $160,029. On average, Mr trades about 48,049 units every 54 days since 2019. As of 30 August 2022 he still owns at least 1,008,758 units of Venus Concept stock.
You can see the complete history of Mr Serafino stock trades at the bottom of the page.
Domenic Serafino is the CEO & Director at Venus Concept.
As the CEO & Director of Venus Concept, the total compensation of Mr Serafino at Venus Concept is $763,479. There are no executives at Venus Concept getting paid more.
Mr Serafino is 60, he's been the CEO & Director of Venus Concept since . There are 3 older and 21 younger executives at Venus Concept. The oldest executive at Venus Concept Inc. is Kenji Shimizu, 68, who is the Interim Chief Innovation Officer.
Domenic's mailing address filed with the SEC is 235 YORKLAND BLVD., SUITE 900, TORONTO, A6, M2J 4Y8.
Over the last 5 years, insiders at Venus Concept have traded over $1,569,538 worth of Venus Concept stock and bought 13,477,963 units worth $14,979,486 . The most active insiders traders include Healthcare Partners, L.P.Ew..., Gilbert H Kliman, eRichard Scott Barry. On average, Venus Concept executives and independent directors trade stock every 46 days with the average trade being worth of $222,494. The most recent stock trade was executed by Michael Willingham Masters ... on 7 June 2024, trading 489,948 units of VERO stock currently worth $587,938.
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss, a device for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; and ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.
Venus Concept executives and other stock owners filed with the SEC include: